Keep Calm and Carry on with Extra Centrosomes

Aberrations in the centrosome number and structure can readily be detected at all stages of tumor progression and are considered hallmarks of cancer. Centrosome anomalies are closely linked to chromosome instability and, therefore, are proposed to be one of the driving events of tumor formation and...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 14; no. 2; p. 442
Main Authors Kalkan, Batuhan Mert, Ozcan, Selahattin Can, Quintyne, Nicholas J, Reed, Samantha L, Acilan, Ceyda
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 17.01.2022
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Aberrations in the centrosome number and structure can readily be detected at all stages of tumor progression and are considered hallmarks of cancer. Centrosome anomalies are closely linked to chromosome instability and, therefore, are proposed to be one of the driving events of tumor formation and progression. This concept, first posited by Boveri over 100 years ago, has been an area of interest to cancer researchers. We have now begun to understand the processes by which these numerical and structural anomalies may lead to cancer, and vice-versa: how key events that occur during carcinogenesis could lead to amplification of centrosomes. Despite the proliferative advantages that having extra centrosomes may confer, their presence can also lead to loss of essential genetic material as a result of segregational errors and cancer cells must deal with these deadly consequences. Here, we review recent advances in the current literature describing the mechanisms by which cancer cells amplify their centrosomes and the methods they employ to tolerate the presence of these anomalies, focusing particularly on centrosomal clustering.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors contributed equally to this work.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14020442